Drugmaker Eli Lilly said Wednesday it would lower the prices of its most frequently used insulins by 70% and expand a program to cap out-of-pocket costs for patients at $35.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.